saRNA LNPs induce neutralization of pseudo- and wild-type SARS-CoV-2 in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
- The study determined what capacity at which antibodies were generated through natural SARS-CoV-2 infection in terms of neutralization of both wild-type and pseudotype SARS-CoV-2 virus. In mice vaccinated with saRNA LNP, there was a highly efficient pseudoviral neutralization varied in a linear dose-dependent manner. The mice that received saRNA LNP vaccine had significantly higher SARS-CoV-2 neutralization compared to the groups receiving pDNA vaccine. All groups that received saRNA LNP vaccine induced higher SARS-CoV-2 neutralization compared to natural SARS-CoV-2 infection in humans.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
saRNA LNPs induce neutralization of pseudo- and wild-type SARS-CoV-2 in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
saRNA LNPs induce high, Th-1 biased antibodies against SARS-CoV-2 in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
SARS-CoV-2 IgG correlates directly with viral neutralization in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Cellular and cytokine responses to saRNA LNP SARS-CoV-2 vaccine in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice